Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Dawah Pharmaceuticals is About to Launch

June 30, 2021 at 16:12 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Dawah Pharmaceuticals has been very active with its suppliers and regulatory partners, preparing its product roll-out to the industry.

NEW YORK, NY, USA, June 30, 2021 /EINPresswire.com/ -- Dawah Pharmaceuticals has been very active with its suppliers and regulatory partners, preparing its product roll-out to the industry.

Our ﬁrst drug, a paralytic, currently has favorable pricing, leading to higher revenues and volumes. We have been issued our NDC number and the label to be placed on the packaging and bottles. The ANDA is currently under review along with ongoing FDA discussions to ensure timely approval.

Our second drug, an antipsychotic, is undergoing preparation to produce stability batches. This drug is going to come in two dosage forms. The purpose of the stability batches is for FDA approval. Dawah is currently reconﬁrming unit dose vial sizes to meet the market demand. Currently, there are increased shortages in the US market, which we anticipated in our earlier feasibility study.

We continue to focus on capital requirements to secure the necessary funding to accelerate the identiﬁed pipeline further. In addition, we are working with potential partners and vendors to strengthen Dawah’s footprint in the market. Institutional investor meetings continue to be ongoing.

We are excited about the next coming months knowing we are near a signiﬁcant milestone. We appreciate our current investors as they believe in our vision and look forward to new investors who can still join a company achieving all that it set out to accomplish.

If you have any questions, please contact me at info@dawahpharma.com.

Nicholas Vartanian
Dawah Pharmaceuticals Inc.
info@dawahpharma.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article